Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer.

Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer. Urol Oncol. 2018 Aug 16;: Authors: Kauffmann G, Arif F, Patel P, Oto A, Liauw SL Abstract PURPOSE: The purpose of this study was to investigate the utility of pre-treatment multiparametric magnetic resonance imaging (mpMRI) in a modern cohort of intermediate and high-risk prostate cancer patients treated with primary radiotherapy. METHODS AND MATERIALS: One hundred twenty three men with National Comprehensive Cancer Network (NCCN) intermediate or high-risk prostate cancer were treated with primary EBRT and/or brachytherapy and had evaluable pre-treatment mpMRI with endorectal coil. Images were assessed for the presence of radiographic extraprostatic extension (rEPE), seminal vesicle invasion (rSVI), lymph node involvement (LNI), sextant involvement, and largest axial tumor diameter. Imaging characteristics were analyzed along with clinical risk factors against freedom from biochemical failure (FFBF). Median follow-up time was 50 months. RESULTS: Fourteen (11%) men developed biochemical failure. The 5-year FFBF was 94% in intermediate-risk patients and 82% in high-risk patients (p
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research

Related Links:

Purpose: The availability of novel imaging modalities (NIM) in prostate cancer (PCa) has overtaken the evidence informing their use. The recent EORTC consensus statement on modern imaging recognises the need for large-scale clinical trials of novel imaging [1]. The UK environment is well placed to conduct such trials; the NCRI prostate cancer CSG wished to benchmark current UK imaging availability and practice to inform future national trials.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The role of pelvic nodal irradiation in prostate cancer remains controversial. Nevertheless, many high-risk patients are treated with prostate and pelvis radiotherapy in addition to androgen deprivation therapy (ADT) [1]. A recent retrospective study [2] and data from the UK Stampede control arm [3] suggest that radiotherapy may be of benefit to node positive patients. The aim of our study was to document outcomes in patients with node positive prostate cancer treated with pelvic nodal radiotherapy in a UK cancer centre.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Relapsed or progressive prostate cancer frequently manifests as consecutive PSA rises long before disease is clinically detectable. Imaging with novel radiotracers targeting prostate-specific membrane antigen (PSMA) has been shown to be more sensitive in identifying the site of disease at lower PSA levels compared with conventional imaging, which may provide increased opportunity for salvage therapy, more aggressive local management of oligometastatic disease or increased confidence in proceeding with systemic therapy [1].
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: To assess the benefits and risks of co-administering maintenance prednisolone with docetaxel and androgen-deprivation therapy (ADT) in hormone sensitive metastatic prostate cancer (HSMPC).
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: As doctors we are required to take consent for radiotherapy; we typically take written consent [1]. We must tell a patient if a treatment might result in a serious adverse outcome, even if the likelihood is very small [2]. As many cancer centres move towards tumour site-specific consent forms for prostate radiotherapy we wanted to ascertain if there was consensus.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
In this study, we describe our experience with both drugs at the Diana Princess of Wales Hospital (DPoW), Grimsby.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: The STAMPEDE trial has recently shown a benefit in overall survival by irradiating the prostate of patients with newly diagnosed metastatic prostate cancer [1]. This benefit was only shown in patients with low burden of metastatic disease, as per the CHAARTED criteria [2]. The current standard of care for these patients is androgen deprivation therapy ± docetaxel chemotherapy and radiotherapy to symptomatic areas of disease if required. The aim of this audit is to determine the potential number of men with low burden of metastatic disease who may require additional radiotherapy.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Radiotherapy to the prostate in mHSPC improves overall survival and progression-free survival (PFS) for patients with low-volume disease [1]. Radium-223 in metastatic castration resistant prostate cancer improves overall survival [2]. We conducted a prospective phase I/II clinical trial in mHSPC, testing the combination of LHRHa with concurrent pelvic radiotherapy and radium-223.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
Purpose: Prostate cancer in Black men has traditionally been associated with poorer outcomes than in their White counterparts. However, this perception has been largely extrapolated from studies in the localised cancer to the advanced cancer setting, where there have been few studies. We aim to evaluate whether ethnicity influences outcome in the advanced prostate cancer setting based on real-world data.
Source: Clinical Oncology - Category: Radiology Authors: Source Type: research
ABSTRACT Introduction: Use of androgen deprivation therapy (ADT) in carcinoma prostate (CaP) has deleterious effect on bone mineral density (BMD) leading to increase incidence of osteoporosis and skeletal-related events. We evaluated bone health status and impact of bone-directed therapy (BDT) and ADT on BMD in these patients from Jan 2015-Dec 2018. Materials and Method: Baseline bone health was assessed using Tc-99 MDP Bone scan/ DEXA scan for patients on ADT. Monthly zoledronic acid (ZA) was given to high-risk candidates (T-score ≤ 2.5 or previous hip/vertebral fracture) or Skel et al. metastatic patients who were rec...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | MRI Scan | Prostate Cancer | Radiation Therapy | Radiography | Study | Urology & Nephrology